Streetbeat News

Regulatory

BAC

JPM

The FDIC and Federal Reserve have identified shortcomings in the living will plans of four major U.S. banks: Bank of America, Citigroup, Goldman Sachs, and JPMorgan Chase. These plans are crucial for guiding the banks in the event of a collapse. Citigroup's plan was deemed 'not credible,' and all four banks have been asked to address these issues by July 2025.

Portfolio Pulse from Michael Juliano

June 21, 2024 | 8:17 pm

AGAE

Allied Gaming & Entertainment (AGAE) has entered into a termination agreement with Elite Fun Entertainment Limited and its affiliates as of June 15, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 8:11 pm

SOAR

Volato has received a notice from the NYSE regarding continued listing standards. Meanwhile, Campbell Capital Management supports Blackwells' campaign for change at Braemar, urging shareholders to vote for Blackwells' nominees and proposals.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 8:10 pm

BTCUSD

DOGEUSD

ETHUSD

XRPUSD

Cryptocurrency markets are trading lower with significant liquidations. Bitcoin, Ethereum, and Dogecoin are among the notable cryptocurrencies experiencing price changes. Standard Chartered is launching a Bitcoin and Ethereum trading desk, while Binance integrates Tether on TON. A civil securities lawsuit against Ripple advances in California.

Portfolio Pulse from Khyathi Dalal

June 21, 2024 | 8:01 pm

TAK

VGK

Takeda has received European Commission approval for FRUZAQLA (fruquintinib) for the treatment of metastatic colorectal cancer in adults previously treated with standard therapies. This approval follows a positive CHMP opinion and previous FDA approval, and is based on results from the Phase 3 FRESCO-2 trial. FRUZAQLA is the first novel targeted therapy in the EU for mCRC regardless of biomarker status in over a decade.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 8:01 pm

LLY

Eli Lilly announced positive results from its SURMOUNT-OSA Phase 3 trials evaluating tirzepatide for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. The drug achieved all primary and key secondary endpoints, including up to a 62.8% reduction in the apnea-hypopnea index. Lilly has submitted tirzepatide for FDA approval and will initiate submissions to other global regulatory agencies.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 7:51 pm

AAWH

CBSTF

HITI

TSNDF

VRNOF

The New York Cannabis Control Board approved home cultivation rules, allowing adults to grow weed at home. New cannabis retail locations are opening in New York, Maryland, Florida, Ohio, Illinois, Virginia, and beyond US borders. Companies like TerrAscend, Verano Holdings, Klutch Cannabis, The Cannabist Company, Ascend Wellness, and High Tide are expanding their retail footprints.

Portfolio Pulse from Jelena Martinovic

June 21, 2024 | 7:32 pm

LMT

Sikorsky Support Services and Derco Aerospace have agreed to pay $70 million to settle False Claims Act allegations related to improper markups on spare parts for Navy trainer aircraft, according to the U.S. Justice Department.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 7:03 pm

MNTS

Momentus has been granted continued listing on Nasdaq by a hearings panel, contingent on filing Form 10-Q by October 14. The company plans to file the form as soon as practicable.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2024 | 7:00 pm

AREB

CRKN

FDS

KAVL

SHCR

SRPT

SWBI

U.S. stocks traded mixed with the Nasdaq Composite moving lower. FactSet Research Systems posted better-than-expected earnings, leading to a 3% rise in its stock. American Rebel Holdings, Sharecare, and Sarepta Therapeutics saw significant gains due to various positive developments, while Kaival Brands Innovations, Crown Electrokinetics, and Smith & Wesson Brands experienced notable declines.

Portfolio Pulse from Avi Kapoor

June 21, 2024 | 6:58 pm